Mylan Loses Bid To Block Teva's Provigil Market Rights
A judge on Monday rejected Mylan Pharmaceuticals Inc.'s argument that Teva Pharmaceuticals USA Inc. and its affiliate Cephalon Inc. had worked together to stymie generic competition of sleep disorder drug Provigil...To view the full article, register now.
Already a subscriber? Click here to view full article